Abstract: The present invention is related to the use of the GHRP-6 and one structural analogue as molecular adjuvants for vaccines. Among other applications, these vaccines may be employed for preventing diseases caused by infectious agents, like viruses, bacteria and ectoparasites, that affect mammals, birds and aquatic organisms. The GHRP-6 and its analogue A233 are effectives as adjuvants when they are combine with a given antigen, since they enhance the specific immune response against it.

Abstract: The present invention is related to the use of the GHRP-6 and one structural analogue as molecular adjuvants for vaccines. Among other applications, these vaccines may be employed for preventing diseases caused by infectious agents, like viruses, bacteria and ectoparasites, that affect mammals, birds and aquatic organisms. The GHRP-6 and its analogue A233 are effectives as adjuvants when they are combine with a given antigen, since they enhance the specific immune response against it.

Abstract: The invention is related with the chemical synthesis for increase the growth rate in marketable fish and crustacean The aim of this invention is supply GHRP-6 to induce directly or indirectly the release of growthing hormone or like, to produce the increase of circulating growthing hormone level in the blood of the fishes. The peptide is stable, soluble and biologically active. The peptide is able to stimulate growth, improve the larvae quality, and increase the defense against pathogen agents, the dry weight, the protein concentration and the RNA in muscle of fish and crustaceans.

Abstract: Peptidic chemical compounds obtained by in silico molecular modelling, having a structure that enables them to perform the same functions of peptidic growth hormone secretagogues. The invention also comprises the preparations containing such compounds and the use in medicines, food additives, nutritional supplements or other formulations of human or animal use.

Abstract: Peptidic chemical compounds obtained by in silico molecular modelling, having a structure that enables them to perform the same functions of peptidic growth hormone secretagogues. The invention also comprises the preparations containing such compounds and the use in medicines, food additives, nutritional supplements or other formulations of human or animal use.

Abstract: This invention relates to a medicine for humans, and particularly to a pharmaceutical combination comprising Epidermal Growth Factor (EGF) and Growth Hormone secretagogue hexapeptide (GHRP) for use in preventing tissue damage due to blood flow suppression by enhancing tissue repair following ischemic damage. The aforementioned combination may be applied as a single pharmaceutical composition. Alternatively, an individual may also receive both EGF and GHRP in a separate manner but within a single therapeutic regime to enhance cellular survival when organs are subjected to blood flow deprivation for a critical period of time. This combination attenuates reactive oxygen species (ROS) formation and its associated cytotoxicity. It is also useful in promoting cellular survival when tissue or organs are exposed to prolonged ischemic periods.